» Articles » PMID: 34282933

The Future of Bacteriophage Therapy Will Promote Antimicrobial Susceptibility

Overview
Journal mSystems
Specialty Microbiology
Date 2021 Jul 20
PMID 34282933
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Rising antimicrobial resistance severely limits efforts to treat infections and is a cause for critical concern. Renewed interest in bacteriophage therapy has advanced understanding of the breadth of species capable of targeting bacterial antimicrobial resistance mechanisms, but many questions concerning ideal application remain unanswered. The following minireview examines bacterial resistance mechanisms, the current state of bacteriophage therapy, and how bacteriophage therapy can augment strategies to combat resistance with a focus on the clinically relevant bacterium Pseudomonas aeruginosa, as well as the role of efflux pumps in antimicrobial resistance. Methods to prevent antimicrobial efflux using efflux pump inhibitors and phage steering, a type of bacteriophage therapy, are also covered. The evolutionary context underlying antimicrobial resistance and the need to include theory in the ongoing development of bacteriophage therapy are also discussed.

Citing Articles

Diagnosing and engineering gut microbiomes.

Cappio Barazzone E, Diard M, Hug I, Larsson L, Slack E EMBO Mol Med. 2024; 16(11):2660-2677.

PMID: 39468301 PMC: 11554810. DOI: 10.1038/s44321-024-00149-4.


Translational research priorities for bacteriophage therapeutics.

Schooley R Essays Biochem. 2024; 68(5):621-631.

PMID: 39417290 PMC: 11652170. DOI: 10.1042/EBC20240020.


StM171, a Bacteriophage That Affects Sensitivity to Antibiotics in Host Bacteria and Their Biofilm Formation.

Jdeed G, Morozova V, Kozlova Y, Tikunov A, Ushakova T, Bardasheva A Viruses. 2023; 15(12).

PMID: 38140696 PMC: 10747581. DOI: 10.3390/v15122455.


Efflux, Signaling and Warfare in a Polymicrobial World.

Moore-Machacek A, Gloe A, OLeary N, Reen F Antibiotics (Basel). 2023; 12(4).

PMID: 37107093 PMC: 10135244. DOI: 10.3390/antibiotics12040731.


Phage Products for Fighting Antimicrobial Resistance.

Huang Y, Wang W, Zhang Z, Gu Y, Huang A, Wang J Microorganisms. 2022; 10(7).

PMID: 35889048 PMC: 9324367. DOI: 10.3390/microorganisms10071324.

References
1.
Harper D, Enright M . Bacteriophages for the treatment of Pseudomonas aeruginosa infections. J Appl Microbiol. 2011; 111(1):1-7. DOI: 10.1111/j.1365-2672.2011.05003.x. View

2.
Torres-Barcelo C, Arias-Sanchez F, Vasse M, Ramsayer J, Kaltz O, Hochberg M . A window of opportunity to control the bacterial pathogen Pseudomonas aeruginosa combining antibiotics and phages. PLoS One. 2014; 9(9):e106628. PMC: 4178015. DOI: 10.1371/journal.pone.0106628. View

3.
Bicalho M, Machado V, Nydam D, Santos T, Bicalho R . Evaluation of oral administration of bacteriophages to neonatal calves: Phage survival and impact on fecal . Livest Sci. 2020; 144(3):294-299. PMC: 7185787. DOI: 10.1016/j.livsci.2011.12.007. View

4.
Aka S, Haji S . Sub-MIC of antibiotics induced biofilm formation of Pseudomonas aeruginosa in the presence of chlorhexidine. Braz J Microbiol. 2015; 46(1):149-54. PMC: 4512058. DOI: 10.1590/S1517-838246120140218. View

5.
Hanlon G, Denyer S, Olliff C, Ibrahim L . Reduction in exopolysaccharide viscosity as an aid to bacteriophage penetration through Pseudomonas aeruginosa biofilms. Appl Environ Microbiol. 2001; 67(6):2746-53. PMC: 92934. DOI: 10.1128/AEM.67.6.2746-2753.2001. View